Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia
Access this Article
Search this Article
Intracellular concentration of imatinib in leukemic cells is thought to affect the clinical efficacy of this drug in patients with chronic myeloid leukemia (CML); however, there is no report that directly indicates the relationship between intracellular concentration and clinical outcome and/or, plasma concentration. In addition, the impacts of genetic variations of drug transporters, which mediate leukocyte concentration of imatinib, are unknown. In the present study, we investigated the correlation between intracellular imatinib concentrations in leukocytes, plasma imatinib levels, and genotypes of drug transporters, including <i>ATP binding cassette B1</i> (<i>ABCB</i>), <i>ABCG2</i>, <i>solute carrier 22A1</i> (<i>SLC22A1</i>), <i>solute carrier organic anion transporter family members 1B1</i> (<i>SLCO1B1</i>) and <i>SLCO1B3</i>. The imatinib levels in leukocytes were determined using HPLC in 15 patients with chronic phase CML. No significant correlation between intracellular and plasma concentrations of imatinib was observed. The intracellular concentration was comparable in both patients with or without complete cytogenetic response. The intracellular imatinib concentration was significantly higher in patients with <i>SLCO1B3</i> 334TT than in those with 334TG/GG (<i>p</i>=0.0188). Plasma concentrations were similar in both <i>SLCO1B3</i> genotypes (<i>p</i>=0.860), thereby resulting in the intracellular to plasma concentration ratio being higher in patients with <i>SLCO1B3</i> 334TT than those with 334 TG/GG (<i>p</i>=0.0502). These results suggested that the <i>SLCO1B3</i> 334T>G polymorphism could have a significant impact on the intracellular concentration of imatinib in leukocytes as a promising biomarker for personalized treatment of CML patients.
- Biological and Pharmaceutical Bulletin
Biological and Pharmaceutical Bulletin 34(1), 114-119, 2011
The Pharmaceutical Society of Japan